5 results on '"Duan, Zhigang"'
Search Results
2. Anthracycline Regimen Adherence in Older Patients with Early Breast Cancer.
- Author
-
BARCENAS, CARLOS H., ZHANG, NING, ZHAO, HUI, DUAN, ZHIGANG, BUCHHOLZ, THOMAS A., HORTOBAGYI, GABRIEL N., and GIORDANO, SHARON H.
- Subjects
AMINOGLYCOSIDES ,BREAST tumors ,CHI-squared test ,COMBINED modality therapy ,CONFIDENCE intervals ,REPORTING of diseases ,EPIDEMIOLOGY ,MEDICARE ,PATIENT compliance ,RESEARCH funding ,LOGISTIC regression analysis ,HEALTH insurance reimbursement ,DATA analysis ,CONTINUING education units ,DATA analysis software ,OLD age ,THERAPEUTICS - Abstract
Background. Rates of anthracycline adherence in breast cancer (BC) patients are unknown, but noncompletion of chemotherapy is associated with worse outcomes. Methods. Using the Surveillance, Epidemiology, and End Results-Medicare database, we obtained demographics, comorbidities, tumor characteristics, and treatment and hospitalization data from stage I-III BC patients diagnosed at age >66 years in 1996-2005 treated with surgery who had anthracycline claims. We compared variables between patients with claims for less than four cycles, considered nonadherent cases, and those with claims for four or more cycles using logistic regression analyses. Results. The sample included 7,399 patients, of whom 1,222 (16.5%) were nonadherent cases. Two hundred forty-three (3.3%) patients had one claim, 298 (4.0%) had two claims, and 681 (9.2%) had three claims. The multivariate regression model showed statistically significant associations between nonadherence and older age, black race, unmarried status, diagnosis before the year 2001, and hospitalizations. Conclusions. Eighty-three percent of older patients with early-stage BC completed at least four cycles of an anthracycline-based chemotherapy regimen. We identified a subset of patients with a higher likelihood of not adhering to the course of treatment. Further research is warranted to develop interventions to enhance adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma.
- Author
-
Tyson, Gia L., Duan, Zhigang, Kramer, Jennifer R., Davila, Jessica A., Richardson, Peter A., and El–Serag, Hashem B.
- Subjects
ALPHA fetoproteins ,LIVER cancer ,HEPATITIS C virus ,CAUSES of death ,CONGESTIVE heart failure ,RETROSPECTIVE studies ,CONFIDENCE intervals - Abstract
Background & Aims: Hepatocellular carcinoma (HCC) can result from hepatitis C virus (HCV)-related liver disease and is the fastest-growing cause of cancer-related death in the United States. α-fetoprotein (AFP) has been used as a prognostic factor for HCC, but the value of AFP as a prognostic factor for HCV-related HCC in the United States is unknown. We investigated whether higher levels of AFP at the time of diagnosis are associated with increased mortality of patients with HCV-related HCC. Methods: In a retrospective study, we collected data from a cohort of HCV-infected veterans, identifying incident HCC cases from October 1, 1998, to January 1, 2007 (n = 1480 patients). The mean serum levels of AFP, obtained within 60 days before to 30 days after HCC diagnosis, were determined for 1064 patients and categorized as less than 10 ng/mL (18%), 10 to less than 100 ng/mL (30%), 100 to less than 1000 ng/mL (22%), or 1000 ng/mL or more (29%). Cox proportional hazard models were used to associate serum levels of AFP with mortality, adjusting for demographic features, clinical factors, and treatment. Results: The median survival times were significantly lower among patients with higher levels of AFP: 709 days for patients with less than 10 ng/mL, 422 days for patients with 10 to less than 100 ng/mL, 208 days for patients with 100 to less than 1000 ng/mL, and 68 days for patients with 1000 ng/mL or more. In the multivariate analysis, increased levels of AFP (10 to <100, 100 to <1000, and ≥1000) were associated significantly with increased mortality, compared with a serum AFP level of less than 10; hazard ratios were 1.50, 2.23, and 4.35, respectively. Conclusions: Serum AFP level at the time of diagnosis with HCV-related HCC is an independent predictor of mortality. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
4. Limits of observational data in determining outcomes from cancer therapy.
- Author
-
Giordano, Sharon H., Yong-Fang Kuo, Zhigang Duan, Hortobagyi, Gabriel N., Freeman, Jean, Goodwin, James S., Kuo, Yong-Fang, and Duan, Zhigang
- Subjects
HEALTH outcome assessment ,SCIENTIFIC observation ,CANCER treatment ,DRUG therapy ,MULTIVARIATE analysis ,CANCER patients ,ANTIANDROGENS ,PROSTATE tumors treatment ,ADENOCARCINOMA ,COLON tumors ,COMBINED modality therapy ,REPORTING of diseases ,LYMPH nodes ,PROSTATE tumors ,PROSTATECTOMY ,RESEARCH funding ,SURVIVAL ,TREATMENT effectiveness ,HORMONE-dependent tumors ,TUMOR treatment ,THERAPEUTICS - Abstract
Background: Observational data are used increasingly to assess the effectiveness of therapies. However, selection biases are likely to have an impact on results and threaten the validity of these studies.Methods: The primary objective of the current study was to explore the effect of selection biases in observational studies of treatment effectiveness in cancer care. Patients were identified from the Surveillance, Epidemiology, and End Results-Medicare linked database. The following groups of patients were included: 5245 men treated with and without androgen deprivation for locally advanced prostate cancer, 43,847 men with active treatment versus observation for low- and intermediate-risk prostate cancer, and 4860 patients with lymph node-positive colon cancer who were treated with and without fluorouracil chemotherapy. Patients were compared by therapy for the outcomes of cancer-specific mortality, other-cause mortality, and overall mortality.Results: In all comparisons, the observational data produced improbable results. For example, when evaluating outcomes of men who were treated with and without androgen deprivation for locally advanced prostate cancer, men who underwent androgen deprivation had higher prostate cancer mortality (hazard ratio, 1.5; 95% confidence interval, 1.29-1.92) despite clinical trial evidence that this treatment improves cancer mortality. Controlling for comorbidity, extent of disease, and other characteristics by multivariate analyses or by propensity analyses had remarkably small impact on these improbable results.Conclusions: The current results suggested that the results from observational studies of treatment outcomes should be viewed with caution. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
5. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.
- Author
-
Kanwal, Fasiha, Kramer, Jennifer R., Duan, Zhigang, Yu, Xiaoying, White, Donna, and El-Serag, Hashem B.
- Abstract
Background & Aims Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States. However, few data are available on recent trends in the incidence and prevalence of NAFLD in the U.S. Methods We analyzed the national Veterans Administration databases from 2003 to 2011 and calculated the age-adjusted prevalence and incidence of NAFLD for the overall sample of patients and by demographic subgroups. We used a previously validated algorithm to define NAFLD, which was based on persistent increases in levels of liver enzymes in the absence of positive results from tests for hepatitis C or hepatitis B or evidence of excessive alcohol use. Results Of the 9,784,541 patients with at least 1 visit to the Veterans Administration between 2003 and 2011, 1,330,600 patients (13.6%) had NAFLD. The annual incidence rates of NAFLD remained stable (from 2.2% to 3.2%) during the study duration. The prevalence of NAFLD increased from 6.3% in 2003 (95% confidence interval, 6.26%–6.3%) to 17.6% in 2011 (95% confidence interval, 17.58%–17.65%), a 2.8-fold increase. The incidence and prevalence increased at significantly greater rates in patients younger than 45 years vs older patients. Conclusions In a U.S. population, the annual incidence of NAFLD ranges from 2% to 3%. The prevalence of NAFLD more than doubled from 2003 through 2011; it is likely to continue to increase because of a steady overall incidence coupled with a rising incidence in younger individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.